Merck’s Zilovertamab Vedotin Achieves 100% Complete Response in Phase 2 DLBCL Trial, Setting Stage for Phase 3

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the first presentation of data from the Phase 2 waveLINE-007 trial evalu...

December 09, 2024 | Monday | News
Amgen’s BLINCYTO® Significantly Improves Disease-Free Survival in Pediatric B-ALL, Redefining Standard of Care

Amgen (NASDAQ:AMGN) announced new data demonstrating that adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease...

December 09, 2024 | Monday | News
Kite Presents Groundbreaking Real-World Data at ASH, Showcasing Yescarta®'s Impact on Relapsed/Refractory Large B-Cell Lymphoma

Kite, a Gilead Company (Nasdaq: GILD), announced findings from three new analyses for Yescarta ® (axicabtagene ciloleucel) that demonstrate i...

December 09, 2024 | Monday | News
Genentech Presents Positive Five-Year Follow-Up Data from POLARIX Study on Polivy® Combination for Untreated DLBCL

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced data from a five-year follow-up of the pivotal Phase III POLARIX study evalu...

December 09, 2024 | Monday | News
Agios Pharmaceuticals Announces Positive Phase 3 ENERGIZE-T Study Results for Mitapivat in Transfusion-Dependent Thalassemia

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases...

December 09, 2024 | Monday | News
Mexico Approves Eisai and Biogen’s LEQEMBI for Early Alzheimer’s Disease Treatment

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...

December 09, 2024 | Monday | News
AstraZeneca’s Imfinzi Gains FDA Approval for Limited-Stage Small Cell Lung Cancer, Offering New Hope for Patients

AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cance...

December 09, 2024 | Monday | News
COFEPRIS Approves LEQEMBI® (Lecanemab) for Early Alzheimer's Disease in Mexico

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...

December 09, 2024 | Monday | News
FDA Accepts Roche's Supplemental Biologics License Application for Columvi® in Combination with GemOx for Relapsed or Refractory DLBCL

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics Licen...

December 09, 2024 | Monday | News
Thermo Fisher Launches Innovative CTS™ Detachable Dynabeads™ to Redefine T Cell Therapy Manufacturing

T cell isolation and controlled release delivers flexibility and control in process development, clinical trials and commercial manufacturing  Ther...

December 05, 2024 | Thursday | News
Duality Biologics Signs Exclusive Option Agreement with GSK for ADC Candidate DB-1324 in Gastrointestinal Cancer

 Duality Biologics ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjuga...

December 04, 2024 | Wednesday | News
Amarna Therapeutics Forms Strategic Partnership with NorthX Biologics to Advance Gene Therapy Development

Amarna Therapeutics, (“Amarna” or “the Company”), a privately held biotechnology company specializing in transformative gene therap...

December 04, 2024 | Wednesday | News
Merck’s Sacituzumab Tirumotecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthroug...

December 04, 2024 | Wednesday | News
Smart Immune and CELLforCURE Partner to Scale SMART101 Production for Advanced Cell Therapy Trials

Smart Immune, a clinical-stage biotechnology company, and CELLforCURE by SEQENS, a Contract  Development and Manufacturing Organization (CDMO) for Adv...

December 03, 2024 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close